Relypsa: Seeking trifecta against kidney disease, biotech team lines up $150 million IPO
They built and sold Ilypsa and Relypsa, now this team is prepping their latest company to ask the FDA to approve another drug for chronic kidney disease patients.
Read full article »
Relypsa develops polymeric drugs for cardiovascular, metabolic and renal diseases.
Read more